Clinical trial
Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
NCT07193966 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
- Lead sponsor
- Shenzhen Geno-Immune Medical Institute
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- September 1, 2025
- Completion date
- July 31, 2026
- Enrollment
- 100 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.